Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections
Authors:
- 1 November 2012
- journal article
- case report
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (11) , 6001-6002
Abstract
Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole “boosting” effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.Keywords
This publication has 10 references indexed in Scilit:
- Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysisJournal of Infection and Chemotherapy, 2012
- Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in PatientsAntimicrobial Agents and Chemotherapy, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel TherapyClinical Pharmacology & Therapeutics, 2011
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety OutcomesClinical Infectious Diseases, 2008
- Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipientsCancer, 2007
- Voriconazole Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2006
- Effect of omeprazole on the steady‐state pharmacokinetics of voriconazoleBritish Journal of Clinical Pharmacology, 2003
- Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisNew England Journal of Medicine, 2002
- Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation RegimensAntimicrobial Agents and Chemotherapy, 2002
- Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.1997